FR2878861B1 - Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a legionella pneumophila - Google Patents

Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a legionella pneumophila

Info

Publication number
FR2878861B1
FR2878861B1 FR0413063A FR0413063A FR2878861B1 FR 2878861 B1 FR2878861 B1 FR 2878861B1 FR 0413063 A FR0413063 A FR 0413063A FR 0413063 A FR0413063 A FR 0413063A FR 2878861 B1 FR2878861 B1 FR 2878861B1
Authority
FR
France
Prior art keywords
prevention
legionella pneumophila
vitro diagnosis
new proteins
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0413063A
Other languages
English (en)
Other versions
FR2878861A1 (fr
Inventor
Jean Philippe Arie
Camille Cyncynatus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Claude Bernard Lyon 1 UCBL
Diaxonhit SA
Original Assignee
Universite Claude Bernard Lyon 1 UCBL
Abag SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Claude Bernard Lyon 1 UCBL, Abag SA filed Critical Universite Claude Bernard Lyon 1 UCBL
Priority to FR0413063A priority Critical patent/FR2878861B1/fr
Priority to PCT/FR2005/001548 priority patent/WO2006010805A2/fr
Priority to EP05778861A priority patent/EP1769249B1/fr
Priority to AT05778861T priority patent/ATE441865T1/de
Priority to DE602005016417T priority patent/DE602005016417D1/de
Publication of FR2878861A1 publication Critical patent/FR2878861A1/fr
Application granted granted Critical
Publication of FR2878861B1 publication Critical patent/FR2878861B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/126—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Legionella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
FR0413063A 2004-06-29 2004-12-08 Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a legionella pneumophila Expired - Fee Related FR2878861B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR0413063A FR2878861B1 (fr) 2004-12-08 2004-12-08 Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a legionella pneumophila
PCT/FR2005/001548 WO2006010805A2 (fr) 2004-06-29 2005-06-21 Nouveaux polypeptides pour la mise en evidence in vitro et la prevention des infections a legionella pneumophila
EP05778861A EP1769249B1 (fr) 2004-06-29 2005-06-21 Nouveaux polypeptides pour la mise en évidence in vitro et la prévention des infections à legionella pneumophila
AT05778861T ATE441865T1 (de) 2004-06-29 2005-06-21 Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
DE602005016417T DE602005016417D1 (de) 2004-06-29 2005-06-21 Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0413063A FR2878861B1 (fr) 2004-12-08 2004-12-08 Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a legionella pneumophila

Publications (2)

Publication Number Publication Date
FR2878861A1 FR2878861A1 (fr) 2006-06-09
FR2878861B1 true FR2878861B1 (fr) 2010-09-17

Family

ID=34951569

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0413063A Expired - Fee Related FR2878861B1 (fr) 2004-06-29 2004-12-08 Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a legionella pneumophila

Country Status (1)

Country Link
FR (1) FR2878861B1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2302489B1 (es) * 2008-03-04 2009-10-27 Guserbiot, S.L Procedimiento para la deteccion de legionella spp mediante anticuerpo policlonal.
US8785145B2 (en) 2011-08-11 2014-07-22 Ingen Biosciences Method for diagnosing gram-negative infections

Also Published As

Publication number Publication date
FR2878861A1 (fr) 2006-06-09

Similar Documents

Publication Publication Date Title
EP2057465A4 (fr) Protéines spécifiques d'organes et procédés d'utilisation
HK1203960A1 (en) Human protein tyrosine phosphatase inhibitors and their pharmaceutical use
DK1988163T3 (da) Hla-a*3303-begrænset wt1 peptid og farmaceutisk sammensætning omfattende det samme
BRPI0716354A2 (pt) "composiÇço e mÉtodo"
HK1159686A1 (en) Hla-a1101-restricted wt1 peptide and pharmaceutical composition comprising same hla-a1101 wt1
DK1973429T3 (da) Proteinhydrolysater og fremgangsmåde til fremstilling
EP1812049A4 (fr) Inhibiteurs de kallikreine et leurs utilisations
DK2059535T3 (da) Prlr-specifikt antistof og anvendelser deraf
BRPI0811666A2 (pt) "sistemas e métodos para fabricação de escalas de deslocamento"
DK3263589T3 (da) Peptidesekvenser og sammensætninger
NO20091424L (no) Substituerte amider, fremgangsmåte for fremstilling derav og anvendelse derav
GB2425352B (en) System and method of determining orientation information
PT2592072T (pt) Inibidores de proteína tirosina fosfatase humana e sua utilização
ITMI20050302A1 (it) Dispositivo di convogliamento e scarico dell'acqua
NO20092217L (no) Agonist TrkB antistoffer og anvendelser derav
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
ITVI20050059A1 (it) Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
ZA200702938B (en) Peptides and APL-type derivatives of Hsp60 and pharmaceutical compositions
EP2059357A4 (fr) Identification et réduction des défauts dans une bande mince de coulée
PL2068922T3 (pl) Przeciwciała anty-IL-13R alfa1 i ich zastosowania
FR2878861B1 (fr) Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a legionella pneumophila
TWI372762B (en) Amino derivatives of b-homoandrostanes and b-heteroandrostanes
BRPI0615481A2 (pt) peptídeos antigênicos e sua utilização
FR2886312B1 (fr) Nouvelles proteines permettant la mise en evidence in vitro et la prevention des infections a streptococcus pyogenes
EP2049679A4 (fr) Procédés et substances pour analyse in vitro et/ou utilisation de protéines associées à des membranes, de parties de celles-ci variantes de ceux-ci

Legal Events

Date Code Title Description
AU Other action affecting the ownership or exploitation of an industrial property right
CD Change of name or company name
TQ Partial transmission of property

Owner name: UNIVERSITE CLAUDE BERNARD LYON 1, FR

Effective date: 20150202

Owner name: DIAXONHIT, FR

Effective date: 20150202

PLFP Fee payment

Year of fee payment: 12

ST Notification of lapse

Effective date: 20170831